» Articles » PMID: 31936880

Design, Synthesis, and Evaluation of Novel 2-Methoxyestradiol Derivatives As Apoptotic Inducers Through an Intrinsic Apoptosis Pathway

Overview
Journal Biomolecules
Publisher MDPI
Date 2020 Jan 16
PMID 31936880
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

In order to discover novel derivatives in the anti-tumor field, reported anti-tumor pharmacophores (uridine, uracil, and thymine) were combined with 2-methoxyestradiol, which has been characterized as having excellent biological properties in terms of anti-tumor activity. Thus, 20 hybrids were synthesized through etherification at the 17β-OH or 3-phenolic hydroxyl group of 2-methoxyestradiol, and evaluated for their biological activities against the human breast adenocarcinoma MCF-7 cell lines, human breast cancer MDA-MB-231 cell lines, and the normal human liver L-O2 cell lines. As a result, all the uridine derivatives and single-access derivatives of uracil/thymine possessed good anti-proliferative activity against tested tumor cells (half maximal inhibitory concentration values from 3.89 to 19.32 µM), while only one dual-access derivative (21b) of thymine possessed good anti-proliferative activity (half maximal inhibitory concentration ≈ 25 µM). Among them, the uridine derivative 11 and the single-access derivative of uracil 12a possessed good anti-proliferative selectivity against tested tumor cells. Furthermore, basic mechanism studies revealed that hybrids 11 and 12a could induce apoptosis in MCF-7 cells through mitochondrial pathway. These hybrids induced morphological changes in MCF-7 cells, causing mitochondrial depolarization. These two hybrids also had the following effects: arrest of the cell cycle at the G2 phase; upregulation of Apaf-1, Bax, and cytochrome c; downregulation of Bcl-2 and Bcl-xL for both mRNA and protein; and increase of the expression for caspase-8 and -9. Finally, apoptotic effector caspase-3 was increased, which eventually caused nuclear apoptosis at least through an intrinsic pathway in the mitochondria. Additionally, hybrids 11 and 12a could specifically bind to estradiol receptor alpha in a dose-dependent manner.

Citing Articles

2-Methoxyestradiol Damages DNA in Glioblastoma Cells by Regulating nNOS and Heat Shock Proteins.

Bastian P, Daca A, Ploska A, Kuban-Jankowska A, Kalinowski L, Gorska-Ponikowska M Antioxidants (Basel). 2022; 11(10).

PMID: 36290736 PMC: 9598669. DOI: 10.3390/antiox11102013.


Self-Nanoemulsifying Drug Delivery System of 2-Methoxyestradiol Exhibits Enhanced Anti-Proliferative and Pro-Apoptotic Activities in MCF-7 Breast Cancer Cells.

Al-Qahtani S, Bin-Melaih H, Atiya E, Fahmy U, Binmahfouz L, Neamatallah T Life (Basel). 2022; 12(9).

PMID: 36143405 PMC: 9503162. DOI: 10.3390/life12091369.


Evidence for 2-Methoxyestradiol-Mediated Inhibition of Receptor Tyrosine Kinase RON in the Management of Prostate Cancer.

Batth I, Huang S, Villarreal M, Gong J, Chakravarthy D, Keppler B Int J Mol Sci. 2021; 22(4).

PMID: 33673346 PMC: 7918140. DOI: 10.3390/ijms22041852.

References
1.
Peyrat J, Brion J, Alami M . Synthetic 2-methoxyestradiol derivatives: structure-activity relationships. Curr Med Chem. 2012; 19(24):4142-56. DOI: 10.2174/092986712802430072. View

2.
Wang C, Li L, Fu D, Qin T, Ran Y, Xu F . Discovery of chalcone-modified estradiol analogs as antitumour agents that Inhibit tumour angiogenesis and epithelial to mesenchymal transition. Eur J Med Chem. 2019; 176:135-148. DOI: 10.1016/j.ejmech.2019.04.071. View

3.
Harrison M, Hahn N, Pili R, Oh W, Hammers H, Sweeney C . A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC). Invest New Drugs. 2010; 29(6):1465-74. PMC: 3042040. DOI: 10.1007/s10637-010-9455-x. View

4.
Tao H, Mei J, Tang X . The anticancer effects of 2-methoxyestradiol on human huh7 cells in vitro and in vivo. Biochem Biophys Res Commun. 2019; 512(3):635-640. DOI: 10.1016/j.bbrc.2019.02.068. View

5.
Verenich S, Gerk P . Therapeutic promises of 2-methoxyestradiol and its drug disposition challenges. Mol Pharm. 2010; 7(6):2030-9. PMC: 3059899. DOI: 10.1021/mp100190f. View